

Table Relative risks (95% CI) of main outcomes (SSRIs versus placebo) for published data, unpublished data and, where possible, combined data

<b>Outcomes</b>	<b>Non-remission</b>	<b>Non-response to treatment</b>	<b>Standardised mean difference in</b>			<b>Discontinuation of treatment due to adverse events</b>	<b>Suicidal behaviour</b>	<b>Suicidal attempt or ideation</b>
			<b>depressive symptoms scores (95% CI)</b>	<b>Serious adverse events</b>	<b>Suicidal behaviour</b>			
<i>Fluoxetine</i>								
Published	0.78 (0.67 to 0.90)	0.67 (0.52 to 0.87)	CDS-R: -0.43 (-0.65 to -0.20)	0.25 (0.03 to 2.22)	1.19 (0.18 to 7.85)	Not stated	Not stated	
Unpublished	Not stated	Not stated	Not stated	Not stated	Not stated	0.94 (0.37 to 2.40)	1.26 (0.36 to 4.40)	
<i>Paroxetine</i>								
Published	0.72 (0.52 to 0.92)	0.79 (0.55 to 1.03)	HAM-D: -0.21 (-0.41 to -0.01)	5.15 (1.17 to 9.13)	1.40 (0.52 to 2.28)	Not stated	10.30	



Outcomes	Non-remission	Non-response to treatment	Standardised mean difference in			Discontinuation of treatment due to adverse events	Suicidal behaviour	Suicidal attempt or ideation
			depressive symptoms scores (95% CI)	Serious adverse events	Suicidal behaviour			
								to 1.38)
<i>Citalopram</i>								
Unpublished	Not stated	Not stated	CDRS-R: -0.34 (-0.64 to -0.04)	1.13 (1.01 to 1.27)	1.20 (0.62 to 2.35)	Not stated	1.99 (0.83 to 4.77)	
<i>Venlafaxine</i>								
Published	Not stated	Not stated	CDRS-R: 0.25 (-0.44 to 0.93)	Not stated	Not stated	Not stated	Not stated	Not stated
Unpublished	Not stated	Not stated	CDRS-R: -0.29 (-0.51 to -0.07)	Not stated	3.46 (1.30 to 9.21)	Not stated	13.77 (1.83 to 103.61)	

